Gong Y, et al. - Investigators analyzed 84 individuals to examine the predictors of response, or resistance, to topical diphenylyclopropenone (DPCP) immunotherapy in subjects with alopecia areata (AA). They recorded a negative association of response rate with hair loss extent. Although, 56.1% of cases responded to DPCP with competent hair regrowth. They noticed higher levels of serum IL-4 pre-treatment and lower levels of IL-12 among non-responders vs responders to DPCP. They observed a relationship between adverse side-effects development and higher pre-treatment serum IgE levels. Hence, they suggested pre-treatment elevated serum total IgE as a predictor for increased risk for severe adverse side-effects to DPCP application.